New hope for tough UC cases: experimental drug ATH-063 enters Mid-Stage trial
NCT ID NCT07513181
First seen Apr 09, 2026 · Last updated May 02, 2026 · Updated 3 times
Summary
This study tests an experimental drug called ATH-063 for people with moderate to severe ulcerative colitis (UC) who have not responded to other advanced treatments. About 120 adults will receive either the drug or a placebo to see if it can reduce symptoms like diarrhea and bleeding and improve colon healing. The goal is to find a new option for managing this chronic autoimmune disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.